Recent biochemical approaches in cancer treatment: a review

مراجع و منابع این مقاله:

• Porta, C., Paglino, C., & Mosca, A. (2014). Targeting PI3K/Akt/mTOR ...
• Roskoski, R. (2012). ERK1/2 MAP kinases: structure, function, and regulation. ...
• Vihinen, P., & Kähäri, V. M. (2002). Matrix metalloproteinases in ...
• Warburg, O. (1956). On the origin of cancer cells. Science, ...
• Yarden, Y., & Pines, G. (2012). The ERBB network: at ...
• Falkenberg, K. J., & Johnstone, R. W. (2014). Histone deacetylases ...
• Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic ...
• Senter, P. D., & Springer, C. J. (2001). Selective activation ...
• Greco, O., & Dachs, G. U. (2001). Gene directed enzyme ...
• Ganapathy-Kanniappan, S., & Geschwind, J. F. H. (2013). Tumor glycolysis ...
• Xie, H. et al. (2014). LDHA inhibition in human pancreatic ...
• Gross, M. I. et al. (2014). Antitumor activity of the ...
• Menendez, J. A., & Lupu, R. (2007). Fatty acid synthase ...
• Svensson, R. U. et al. (2016). Inhibition of acetyl-CoA carboxylase ...
• Stein, E. M. et al. (2017). Enasidenib in mutant IDH2 ...
• Schröder, F. H. et al. (2009). Screening and prostate-cancer mortality ...
• Trevisani, F. et al. (2001). Serum alpha-fetoprotein for diagnosis of ...
• Jacobs, I. et al. (1993). A risk of malignancy index ...
• Slamon, D. J. et al. (2001). Use of chemotherapy plus ...
• Karapetis, C. S. et al. (2008). K-ras mutations and benefit ...
• Early Breast Cancer Trialists' Collaborative Group (EBCTCG). (2011). Relevance of ...
• Garon, E. B. et al. (2015). Pembrolizumab for the treatment ...
• Druker, B. J. et al. (2001). Efficacy and safety of ...
• Robson, M. et al. (2017). Olaparib for metastatic breast cancer ...
• Bettegowda, C. et al. (2014). Detection of circulating tumor DNA ...
• Zhang, W. et al. (2015). Exosomes in cancer: small particle, ...
• Lu, Y. et al. (2020). Safety and feasibility of CRISPR-edited ...
• Liu, Y. et al. (2019). CRISPR/Cas9-mediated gene editing of KRAS ...
• Li, J. et al. (2017). Targeting BRAF mutations in melanoma ...
• Haapaniemi, E. et al. (2018). CRISPR–Cas9 genome editing induces a ...
• Jinek, M. et al. (2012). A programmable dual-RNA-guided DNA endonuclease ...
• Shalem, O. et al. (2014). Genome-scale CRISPR-Cas9 knockout screening in ...
• Lino, C. A. et al. (2018). Delivering CRISPR: a review ...
• Barenholz, Y. (2012). Doxil®—the first FDA-approved nano-drug: lessons learned. Journal ...
• Allen, T. M., & Cullis, P. R. (2013). Liposomal drug ...
• Danhier, F. et al. (2012). PLGA-based nanoparticles: an overview of ...
• Govender, T. et al. (2000). PLGA nanoparticles for drug delivery: ...
• Dreaden, E. C. et al. (2012). The golden age: gold ...
• Laurent, S. et al. (2011). Magnetic iron oxide nanoparticles: synthesis, ...
• Ramasamy, T. et al. (2014). Smart polymeric nanoplatforms for cancer ...
• Needham, D. et al. (2000). Temperature-sensitive liposomes for the delivery ...
• Vader, P. et al. (2016). Extracellular vesicles for drug delivery. ...
• Verma, S. et al. (2012). Trastuzumab emtansine for HER2-positive advanced ...
• Dagogo-Jack, I. & Shaw, A. T. (2018). Tumor heterogeneity and ...
• Blanco, E. et al. (2015). Principles of nanoparticle design for ...
• Charlesworth, C. T. et al. (2019). Identification of preexisting adaptive ...
• Prasad, V. et al. (2018). The high price of anticancer ...
• Hood, L. & Friend, S. H. (2011). Predictive, personalized, preventive, ...
• Ogretmen B. Sphingolipid metabolism in cancer signalling and therapy. Nature ...
• Saddoughi SA, Ogretmen B. Diverse functions of ceramide in cancer ...
• Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nature Reviews ...
نمایش کامل مراجع